|
Aug 3
|
Job market concerns take center stage as earnings season rolls on: What to watch this week
|
|
Aug 3
|
What To Expect From Hims & Hers Health’s (HIMS) Q2 Earnings
|
|
Aug 1
|
Earnings, Fed commentary, consumer credit: What to Watch
|
|
Aug 1
|
McDonald’s, Palantir, Novo Nordisk Earnings: What to Watch Next Week
|
|
Aug 1
|
Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem.
|
|
Aug 1
|
Hims & Hers Stock to Report Q2 Earnings: What's in the Cards?
|
|
Aug 1
|
Palantir, AMD, Shopify Headline Another Busy Week of Tech Earnings
|
|
Aug 1
|
Healthcare Triangle Surges Forward: QuantumNexis's AI-Driven HIMS Platform 'Ezovion' Now Live on Microsoft Azure Marketplace
|
|
Aug 1
|
Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates
|
|
Jul 31
|
Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare
|
|
Jul 31
|
Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline
|
|
Jul 30
|
Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates
|
|
Jul 30
|
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
|
|
Jul 30
|
Hims & Hers Health Closes In On Buy Point As Earnings Loom
|
|
Jul 30
|
Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
|
|
Jul 30
|
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
|
|
Jul 29
|
3 Stocks That May Be Undervalued By Up To 46.1% Based On Intrinsic Value Estimates
|
|
Jul 29
|
Faire Appoints Former DoorDash COO Christopher Payne to Board of Directors
|
|
Jul 29
|
Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook
|
|
Jul 29
|
Hims & Hers Data Shows Personalized GLP-1 Plans Drive Real Weight Loss, Few Side Effects, and Strong Adherence to Care
|